Pioneering a disruptive
therapeutic modality

Transformative medicines for
Targeted Protein Stabilization

Our Approach

Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.  

The big idea

LIGHTBULB.png

Targeting a shared mechanism driving disease – protein turnover

The challenge

thechallenge_icon.png

123-456-7890

Drugging a universal degradation
signal in a target-specific manner

The solution

thesolution_icon.png

Find us on Facebook

Establishing an adaptable platform
for restoring protein stability

Reduced protein expression or aberrant protein turnover is a common underlying driver of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is a universal tag that marks proteins for destruction and has emerged as a highly sought-after therapeutic target. Although the therapeutic value of augmenting protein stabilization via the UPS has been demonstrated with proteasome inhibitors, these drugs globally inhibit protein degradation in a non-specific manner, limiting their use outside of oncology due to poor tolerability and highlighting the need for targeted approaches.

 

Our Platform

At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. Our RESTORED™ platform generates heterobifunctional small-molecules (RESTORACS™) that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin and restore protein function. We are initially leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

 
 

Who We Are

Stablix is a New York City-based preclinical stage biotechnology company, pioneering small molecule medicines for targeted protein stabilization. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.

Leadership

tony (3) (1).png

Tony Kingsley
CEO

 

IMG_3088_edited.png

Kevin Sprott, PhD
COO
Co-Founder

eddine-saiah.jpg

Eddine Saiah, PhD
CSO

Brian Bowman

Brian Bowman, PhD
SVP of Biology
Co-Founder

DSC03773_edited.jpg

Scott Kanner, PhD
Associate Director 
Platform Sciences 
Co-Founder

Headshot_UKS.jpg

Uddhav Shigdel, PhD
Director
Biomolecular Sciences

yukie-takabatake-phd_edited.jpg

Yukie Takabatake, PhD
Associate Director
Cellular Biology

Scientific Advisors

hcolecraft_edited.jpg

Henry Colecraft, PhD
Chair of SAB

Co-Founder

BMK%20Head%20Shot%202021_edited.jpg

Benedikt Kessler, PhD
University of Oxford
Professor

chris_dinsmore_edited_edited.jpg

Chris Dinsmore, PhD
CSO Kronos Bio

chrisroberts-300x300.jpg

Chris Roberts, PhD
Chief Executive Officer
Civetta Therapeutics

steven hale headshot.jpg

Stephen Hale, PhD
Independent Consultant

andrew_turnbull_headshot_edited.jpg

Andrew Turnbull, PhD
Senior Principal Scientist
CRUK-TDL

H_Mehmet_headshot.jpg

Huseyin Mehmet, PhD
Executive Director, New Ventures
UMass Medical School

mark_saulnier_headshot_edited.jpg

Mark Saulnier, PhD
Former Research Fellow
Bristol-Myers Squibb

IMG_0024.jpg

Megan Yao, PhD
Independent Consultant

jue-chen.jpg

Jue Chen
William E. Ford Professor Investigator, Howard Hughes Medical Institute; National Academy of Sciences

Board of Directors 

Carlo_edited.jpg

Carlo Rizzuto, PhD
Director

Clare.jpg

Clare Ozawa, PhD
Director

Ali.jpeg

Ali Behbahani, MD
Director

tony (3) (1).png

Tony Kingsley
Director

Andy Color.jpg
J. C. Lopez.jpg

Andrew Phillips, PhD
Observer

J.C. Lopez, MD
Observer

 

Our Investors

VER_Logo_2c_Coated.png
NEA_logo.png
CAM%20Logo%20Blue_edited.png
Euclidean%20Capital%20logo_edited.png
ARE_Proprietary_Products_RGB_VentureInve
Stablix_illustrations_careerstransparent

Are you ready to join our team of industry leaders and innovative thinkers? 

We are always seeking to add the best and brightest talent to our team. Check out our careers page to learn more about open positions and opportunities.